|
1
|
Span PN, Sweep FC, Wiegerinck ET,
Tjan-Heijnen VC, Manders P, Beex LV and deKok JB: Survivin is an
independent prognostic marker for risk stratification of breast
cancer patients. Clin Chem. 50:1986–1993. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
The International Agency for Research on
Cancer (IARC). Pathology and Genetics: Tumours of the Breast and
Female Genital Organs. World Health Organization Classification of
Tumours. 4. 3rd edition. Tavassoli FA and Devilee P: IARC Press;
Lyon: 2003
|
|
3
|
Page DL: Special types of invasive breast
cancer, with clinical implications. Am J Surg Pathol. 27:832–835.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weigelt B, Horlings HM, Kreike B, Hayes
MM, Hauptmann M, Wessels LF, de Jong D, Van de Vijver MJ, Van’t
Veer LJ and Peterse JL: Refinement of breast cancer classification
by molecular characterization of histological special types. J
Pathol. 216:141–150. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE
and Børresen-Dale AL: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI
|
|
6
|
Nielsen TO, Hsu FD, Jensen K, Cheang M,
Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler
L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M and Perou
CM: Immunohistochemical and clinical characterization of the
basal-like of invasive breast carcinoma. Clin Cancer Res.
10:5367–5374. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Banerjee S, Reis-Filho JS, Ashley S,
Steele D, Ashworth A, Lakhani SR and Smith IE: Basal-like breast
carcinomas: clinical outcome and response to chemotherapy. J Clin
Pathol. 59:729–735. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheang MC, Voduc D, Bajdik C, Leung S,
McKinney S, Chia SK, Perou CM and Nielsen TO: Basal-like breast
cancer defined by five biomarkers has superior prognostic value
than triple-negative phenotype. Clin Cancer Res. 14:1368–1376.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Laurinavicius A, Laurinaviciene A,
Ostapenko V, Dasevicius D, Jarmalaite S and Lazutka J:
Immunohistochemistry profiles of breast ductal carcinoma: factor
analysis of digital image analysis data. Diagn Pathol. 7:272012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carey LA, Perou CM, Livasy CA, Dressler
LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S,
Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS
and Millikan RC: Race, breast cancer subtypes, and survival in the
Carolina Breast Cancer Study. JAMA. 295:2492–2502. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Morrison DH, Rahardja D, King E, Peng Y
and Sarode VR: Tumour biomarker expression relative to age and
molecular subtypes of invasive breast cancer. Br J Cancer.
107:382–387. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Geyer FC, Rodrigues DN, Weigelt B and
Reis-Filho JS: Molecular classification of estrogen
receptor-positive/luminal breast cancer. Adv Anat Pathol. 19:39–53.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bertucci F, Finetti P, Cervera N, Esterni
B, Hermitte F, Viens P and Birnbaum D: How basal are
triple-negative breast cancers? Int J Cancer. 123:236–240. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
de Ruijter TC, Veeck J, de Hoon JP, van
Engeland M and Tjan-Heijnen VC: Characteristics of triple-negative
breast cancer. J Cancer Res Clin Oncol. 137:183–192.
2011.PubMed/NCBI
|
|
15
|
Nakagawa M, Bando Y, Nagao T, Takai C,
Ohnishi T, Honda J, Moriya T, Izumi K, Takahashi M, Tangoku A and
Sasa M: Among triple-negative breast cancers, HER2 (0) breast
cancer shows a strong tendency to be basal-like compared with HER2
(1+) breast cancer: preliminary results. Breast Cancer. 19:54–59.
2012.PubMed/NCBI
|
|
16
|
Duffy MJ, O’Donovan N, Brennan DJ,
Gallagher WM and Ryan BM: Survivin: a promising tumor biomarker.
Cancer Lett. 249:49–60. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Adamkov M, Halasova E, Kajo K, Machalekova
K, Vybohova D, Varga I and Rajcany J: Survivin: a promising
biomarker in breast carcinoma. Neoplasma. 57:572–577. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nassar A, Sexton D, Cotsonis G and Cohen
C: Survivin expression in breast carcinoma: correlation with
apoptosis and prognosis. Appl Immunohistochem Mol Morphol.
16:221–226. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dallaglio K, Marconi A and Pincelli C:
Survivin: a dual player in healthy and diseased skin. J Invest
Dermatol. 132:18–27. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, espressed in cancer and
lynphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nassar A, Lawson D, Cotsonis G and Cohen
C: Survivin and caspase-3 expression in breast cancer: correlation
with prognostic parameters, proliferation, angiogenesis, and
outcome. Appl Immunohistochem Mol Morphol. 16:113–120. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Paik S, Shak S, Tang G, Kim C, Baker J,
Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher
ER, Wickerham DL, Bryant J and Wolmark N: A multigene assay to
predict recurrence of tamoxifen-treated, node-negative breast
cancer. N Engl J Med. 351:2817–2826. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chu JS, Shew JY and Huang CS:
Immunohistochemical analysis of survivin espression in primary
breast cancers. J Formos Med Assoc. 103:925–931. 2004.PubMed/NCBI
|
|
24
|
Kennedy SM, O’Driscoll L, Purcell R,
Fitz-Simons N, McDermott EW, Hill AD, O’Higgins NJ, Parkinson M,
Linehan R and Clynes M: Prognostic importance of survivin in breast
cancer. Br J Cancer. 88:1077–1083. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hinnis AR, Luckett JC and Walker RA:
Survivin is an independent predictor of short-term survival in poor
prognostic breast cancer patients. Br J Cancer. 96:639–645. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Caldas H, Jiang Y, Holloway MP, Fangusaro
J, Mahotka C, Conway EM and Altura RA: Survivin splice variants
regulate the balance between proliferation and cell death.
Oncogene. 24:1994–2007. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brennan DJ, Rexhepaj E, O’Brien SL,
McSherry E, O’Connor DP, Fagan A, Culhane AC, Higgins DG, Jirstrom
K, Millikan RC, Landberg G, Duffy MJ, Hewitt SM and Gallagher WM:
Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic
indicator in breast cancer. Clin Cancer Res. 14:2681–2689. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rexhepaj E, Jirstrom K, O’Connor DP,
O’Brien SL, Landberg G, Duffy MJ, Brennan DJ and Gallagher WM:
Validation of cytoplasmic-to-nuclear ratio of survivin as an
indicator of improved prognosis in breast cancer. BMC Cancer.
10:6392010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gunduz E, Gunduz M, Beder L, Nagatsuka H,
Fukushima K, Sutcu R, Delibas N, Yamanaka N, Shimizu K and Nagai N:
Downregulation of TESTIN and its association with cancer history
and a tendency toward poor survival in head and neck squamous cell
carcinoma. Arch Otolaryngol Head Neck Surg. 135:254–260. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tatarelli C, Linnenbach A, Minori K and
Croce CM: Characterization of the human TESTIN gene localized in
the FRA7G region at 7q31.2. Genomics. 68:1–12. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Weeks RJ, Kees UR, Song S and Morison IM:
Silencing of TESTIN by dense biallelic promoter methylation is the
most common molecular event in childhood acute lymphoblastic
leukaemia. Mol Cancer. 9:1632010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ma H, Weng D, Chen Y, Huang W, Pan K, Wang
H, Sun J, Wang Q, Zhou Z, Wang H and Xia J: Extensive analysis of
D7S486 in primary gastric cancer supports TESTIN as a candidate
tumor suppressor gene. Mol Cancer. 9:1902010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu X, Cicek MS, Plummer SJ, Jorgenson E,
Casey G and Witte JS: Association of testis derived transcript gene
variants and prostate cancer risk. J Urol. 177:894–898. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sarti M, Sevignani C, Calin GA, Aqeilan R,
Shimizu M, Pentimalli F, Picchio MC, Godwin A, Rosenberg A, Drusco
A, Negrini M and Croce CM: Adenoviral transduction of TESTIN gene
into breast and uterine cancer cell lines promotes apoptosis and
tumor reduction in vivo. Clin Cancer Res. 11:806–813.
2005.PubMed/NCBI
|
|
35
|
Tobias ES, Hurlstone AF, Mackenzie E,
McFarlane R and Black DM: The TES gene at 7q31.1 is methylated in
tumours and encodes a novel growth-suppressing LIM domain protein.
Oncogene. 20:2844–2853. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Coutts AS, MacKenzie E, Griffith E and
Black DM: TES is a novel focal adhesion protein with a role in cell
spreading. J Cell Sci. 116:897–906. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Griffith E, Coutts AS and Black DM: RNAi
knockdown of the focal adhesion protein TES reveals its role in
actin stress fibre organisation. Cell Motil Cytoskeleton.
60:140–152. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Griffith E, Coutts AS and Black DM:
Characterisation of chicken TES and its role in cell spreading and
motility. Cell Motil Cytoskeleton. 57:133–142. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I The value of histological
grade in breast cancer: experience from a large study with
long-term follow-up. Histopathology. 41:154–161. 2002.
|
|
40
|
Union Internationale Contre Cancer;
International Union Against Cancer. TNM Atlas. 5th edition.
Wittekind CH, Hutter R, Greene FL, Klimpfinger M and Sobin LH:
Springer-Verlag; Berlin: 2005, View
Article : Google Scholar
|
|
41
|
Jha K, Shukla M and Pandey M: Survivin
expression and targeting in breast cancer. Surg Oncol. 21:125–131.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Al-Joudi FS, Iskandar ZA, Hasnan J, Rusli
J, Kamal Y, Imran AK, Ahmed M and Zakaria J: Expression of survivin
and its clinicopathological correlations in invasive ductal
carcinoma of the breast. Singapore Med J. 48:607–614.
2007.PubMed/NCBI
|
|
43
|
Fortugno P, Wall NR, Giodini A, O’Connor
DS, Plescia J, Padgett KM, Tognin S, Marchisio PC and Altieri DC:
Survivin exists in immunochemically distinct subcellular pools and
is involved in spindle microtubule function. J Cell Sci.
115:575–585. 2002.PubMed/NCBI
|
|
44
|
Moon WS and Tarnawski AS: Nuclear
translocation of survivin in hepatocellular carcinoma: a key to
cancer cell growth? Hum Pathol. 34:1119–1126. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Knauer SK, Krämer OH, Knösel T, Engels K,
Rödel F, Kovács AF, Dietmaier W, Klein-Hitpass L, Habtemichael N,
Schweitzer A, Brieger J, Rödel C, Mann W, Petersen I, Heinzel T and
Stauber RH: Nuclear export is essential for the tumor-promoting
activity of survivin. FASEB J. 21:207–216. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Stauber RH, Mann W and Knauer SK: Nuclear
and cytoplasmic survivin: molecular mechanism, prognostic, and
therapeutic potential. Cancer Res. 67:5999–6002. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Archacki SR, Angheloiu G, Moravec CS, Liu
H, Topol EJ and Wang QK: Comparative gene expression analysis
between coronary arteries and internal mammary arteries identifies
a role for the TES gene in endothelial cell functions relevant to
coronary artery disease. Hum Mol Genet. 21:1364–1373. 2012.
View Article : Google Scholar
|
|
48
|
Jaenisch R and Bird A: Epigenetic
regulation of gene expression: how the genome integrates intrinsic
and environmental signals. Nat Genet. 33:245–254. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Dworkin AM, Huang TH and Toland AE:
Epigenetic alterations in breast: implications for breast cancer
detection, prognosis and treatment. Semin Cancer Biol. 19:165–171.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Holm K, Hegardt C, Staaf J,
Vallon-Christersson J, Jönsson G, Olsson H, Borg A and Ringnér M:
Molecular subtypes of breast cancer are associated with
characteristic DNA methylation patterns. Breast Cancer Res.
12:R362010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hellman A, Zlotorynski E, Scherer SW,
Cheung J, Vincent JB, Smith DI, Trakhtenbrot L and Kerem B: A role
for common fragile site induction in amplification of human
oncogenes. Cancer Cell. 1:89–97. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Huang H, Qian J, Proffit J, Wilber K,
Jenkins R and Smith DI: FRA7G extends over a broad region:
coincidence of human endogenous retroviral sequences (HERV-H) and
small polydispersed circular DNAs (spcDNA) and fragile sites.
Oncogene. 16:2311–2319. 1998. View Article : Google Scholar
|
|
53
|
Huang H, Qian C, Jenkins RB and Smith DI:
Fish mapping of YAC clones at human chromosomal band 7q31.2:
identification of YACS spanning FRA7G within the common region of
LOH in breast and prostate cancer. Genes Chromosomes Cancer.
21:152–159. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Elgelmann JA, Zhang XL and Lisanti MP:
Genes encoding human caveolin-1 and -2 are co-localized to the
D7S522 locus (7q31.1), a known fragile site (FRA7G) that is
frequently deleted in human cancers. FEBS Lett. 436:403–410. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lin JC, Scherer SW, Tougas L, Traverso G,
Tsui LC, Andrulis IL, Jothy S and Park M: Detailed deletion mapping
with a refined physical map of 7q31 localizes a putative tumor
suppressor gene for breast cancer in the region of MET. Oncogene.
13:2001–2008. 1996.PubMed/NCBI
|
|
56
|
Elsheikh SE, Green AR, Rakha EA, Samaka
RM, Ammar AA, Powe D, Reis-Filho JS and Ellis IO: Caveolin 1 and
Caveolin 2 are associated with breast cancer basal-like and
triple-negative immunophenotype. Br J Cancer. 99:327–334. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Mercier I, Bryant KG, Sotgia F, Bonuccelli
G, Witkiewicz AK, Dasgupta A, Jasmin JF, Pestell RG and Lisanti MP:
Using Caveolin-1 epithelial immunostaining patterns to stratify
human breast cancer patients and predict the Caveolin-1 (P132L)
mutation. Cell Cycle. 8:1396–1401. 2009. View Article : Google Scholar
|
